Navigation Links
Oncolytic viruses mediating anti-tumor immunity in human cancer patients

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research. The therapy program is based on scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.

The results demonstrate an anti-tumor immunity of oncolytic viruses published for the first time in humans and indicate the strong efficacy of the next generation viruses against solid tumor cancers. As of today, 200 patients have been treated with oncolytic virus therapy in the company's Advanced Therapy Access Program.

"This is the first time it has been shown in humans that oncolytic viruses can be used for the induction of anti-tumor immunity. The GMCSF armed oncolytic adenovirus can mediate anti-tumor immunologic responses by recruiting natural killer cells and by the induction of tumor-specific cytotoxic T-cells", explains research professor Akseli Hemminki, the CSO and co-founder of Oncos.

"Anti-tumor immunity plays a major role in the strong efficacy results. We are starting clinical trials with CGTG-102, which is further improved compared of the virus described in this publication", comments Pekka Simula, the CEO and co-founder of Oncos.

The Cancer Research article reports strong safety and efficacy results in patients with advanced cancer progressing after available chemotherapy options. Out of the 15 radiologically evaluable patients 2 had complete responses (13%), 5 patients had stable disease (33 %) and 1 had a partial response (6 %). Therefore, the clinical benefit rate was 47% according to the RECIST criteria. Responses were frequently seen in both injected and non-injected tumors. The safety profile was favorable with no grade 4-5 side effects realized.

"It has been impressive to see how powerful and consistent the oncolytic adenovirus platform is for directing the body's own immune system against tumor cells" says Dr. Vincenzo Cerullo, the scientist who led the project at the University of Helsinki Cancer Gene Therapy Group (CGTG).


Contact: Timo Ahopelto
University of Helsinki

Related medicine news :

1. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
2. Mild-mannered metabolic helper rushes to fight invading viruses, researchers report
3. UBC graduate student finds a start/stop switch for retroviruses
4. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
5. Researchers find broad spectrum antiviral that fights multitude of viruses
6. Compound found that targets wide range of viruses
7. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
8. Poorly understood cell plays role in immunity against the flu
9. BHM Healthcare Congratulates PORT Human Services: First to Receive CABHA Status
10. The cost of medicalizing human conditions
11. It was brawn over beauty in human mating competition
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Eric ... patients the many benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This ... tools traditionally used by a dentist in Gettysburg, PA . From routine ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to ... for dental implants at her Mississauga, ON practice. Dr. Williams has been ... placement of dental implants. , Missing teeth can lead to a variety of ...
(Date:11/24/2015)... Tucson, AZ (PRWEB) , ... November 24, 2015 , ... ... iPlus 2.0™ treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are ... used for frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort ...
(Date:11/24/2015)... ... November 24, 2015 , ... Charitable giving is at its peak ... in the last five weeks of the year totalling over $358 billion in 2014. ... connect the nation’s charities with those individuals who want to “give back” during the ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 25, 2015 WuXi PharmaTech ... ), a leading open-access R&D capability and technology platform ... with operations in China and ... that at an extraordinary general meeting of shareholders held ... proposal to authorize and approve the previously announced agreement ...
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... , Nov. 24, 2015  Natera, ... in non-invasive genetic testing and the analysis ... it will present at the 27 th ... December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., ... financial results, business activities and financial outlook. ...
Breaking Medicine Technology: